What is Zurzuvae prescribed for?
Zurzuvae is prescribed to treat postpartum depression in adults.
What is the name of the drug and what does it do?
Zurzuvae, pronounced ZUR-zoo-vay, (generic name: zuranolone) is a medication approved for treating postpartum depression (PPD) in adults.
It belongs to a class of drugs known as neuroactive steroids, which are used to modify the activity of neurotransmitters in the brain, thereby helping to alleviate depressive symptoms that occur after childbirth.
How does it work?
Zurzuvae acts as a positive modulator of the GABA-A receptors in the brain. GABA (gamma-aminobutyric acid) is a neurotransmitter that reduces the activity of neurons, leading to a calming effect.
By enhancing the action of GABA, Zurzuvae helps to stabilize mood and reduce the symptoms of depression.
What did the research discover?
Clinical trials demonstrated that Zurzuvae significantly improves depressive symptoms in individuals with severe postpartum depression.
The trials, involving 345 patients, showed that those treated with Zurzuvae experienced more substantial improvements in depression scores compared to those who received a placebo.
This effect was consistent across two separate studies, affirming Zurzuvae’s efficacy in alleviating the emotional and psychological challenges of PPD.
What are some of the side effects?
The side effects listed are from the product manufacturer. As health scientists, we share this information to keep you informed without causing undue worry. Many side effects diminish over time, and not all patients experience them. If prescribed medication, take it as directed and consult your healthcare professional if you have any concerning side effects.
- Sleepiness or drowsiness
- Dizziness
- Diarrhea
- Feeling tired or weak
- Nasopharyngitis (common cold)
- Urinary tract infections
What are the dosage recommendations and how is it prescribed?
Zurzuvae is recommended to be taken orally, once daily in the evening, with a fat-containing meal, for a duration of 14 days.
The standard dosage is 50 mg, but it can be adjusted to 40 mg if side effects occur. It can be used alone or in conjunction with other antidepressants.
For patients with severe hepatic impairment (liver problems) or renal impairment (kidney problems), a reduced dose of 30 mg is recommended.
Source:
- Drug Trials Snapshots: ZURZUVAE. FDA. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-zurzuvae. Accessed 2024 July 11.
- Highlights of Prescribing Information for ZURZUVAE. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217369s000lbl.pdf. Accessed 2024 July 11.
